The Journal of Allergy and Clinical Immunology
Volume 116, Issue 4 , Pages 768-772 , October 2005

Effect of combined montelukast and desloratadine on the early asthmatic response to inhaled allergen

  • Beth E. Davis, BSc
    • ,
  • David C. Todd, MD, FRCP(C)
    • ,
  • Donald W. Cockcroft, MD, FRCP(C)

      Affiliations

    • Corresponding Author InformationReprint requests: Donald W. Cockcroft, MD, FRCP(C), Division of Respiratory Medicine, University of Saskatchewan, Ellis Hall, Rm 551, 5th Floor, Saskatoon, SK S7N 0W8 Canada.

Received 25 April 2005 ,Revised 6 June 2005 ,Accepted 13 June 2005.

References 

  1. Rafferty P, Beasley R, Holgate ST. The contribution of histamine to immediate bronchoconstriction provoked by inhaled allergen and adenosine 5′ monophosphate in atopic asthma. Am Rev Respir Dis. 1987;136:369–373
  2. Gong H, Tashkin DP, Dauphinee B, Djahed B, Wu TC. Effects of oral cetirizine, a selective H1 antagonist, on allergen- and exercise-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol. 1990;85:632–641
  3. Rafferty P, Jackson L, Smith R, Holgate ST. Terfenadine, a potent histamine H1-receptor antagonist in the treatment of grass pollen sensitive asthma. Br J Clin Pharmacol. 1990;30:229–235
  4. Cockcroft DW, Keshmiri M, Murdock KY, Gore BC. Allergen induced increase in airway responsiveness is not inhibited by acute treatment with ketotifen or clemastine. Ann Allergy. 1992;68:245–250
  5. Bentley AM, Walker S, Hanotte F, De Vos C, Durham SR. A comparison of the effects of oral cetirizine and inhaled beclomethasone on early and late asthmatic responses to allergen and the associated increase in airways hyperresponsiveness. Clin Exp Allergy. 1996;26:909–917
  6. Dahlen S-E, Dahlen B, Eliasson E, Johansson H, Bjorck T, Kumlin M, et al. Inhibition of allergic bronchoconstriction in asthmatics by the leukotriene-antagonist ICI-204,219. Adv Prostaglandin Thromboxane Leukot Res. 1991;21A:461–464
  7. Taylor IK, O'Shaughnessy KM. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperactivity in atopic subjects. Lancet. 1991;337:690–694
  8. Diamant Z, Timmers MC, van der Veen H, Friedman BS, De Smet M, Depre M, et al. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J Allergy Clin Immunol. 1995;95:42–51
  9. Hamilton AL, Watson RM, Wyile G, O'Byrne PM. Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005. Thorax. 1997;52:348–354
  10. Hamilton A, Faiferman I, Stober P, Watson RM, O'Byrne PM. Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early-and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects. J Allergy Clin Immunol. 1998;102:177–183
  11. Cockcroft DW, Murdock KY, Kirby J, Hargreave FE. Prediction of airway responsiveness to allergen from skin sensitivity to allergen and airway responsiveness to histamine. Am Rev Respir Dis. 1997;135:264–267
  12. Cockcroft DW, Murdock KY. Changes in bronchial responsiveness to histamine at intervals after allergen challenge. Thorax. 1987;42:302–308
  13. Cockcroft DW, Murdock KY, Mink JT. Determination of histamine PC20: comparison of linear and logarithmic interpolation. Chest. 1983;84:505–506
  14. Cockcroft DW, McParland CP, O'Byrne PM, Friend JL, Rutherford BC, Swystun VA. Beclomethasone given after the early asthmatic response inhibits the late response and the increased methacholine responsiveness and cromolyn does not. J Allergy Clin Immunol. 1993;91:1163–1168
  15. Web based program for computing various sample sizes. Statistical considerations for clinical trials and scientific experiments. MGH Biostatistics Software, 2003. Available at: www.hedwig.mgh.harvard.edu/sample_sizesize.html. Accessed June 3, 2005.
  16. Town GI, Holgate ST. Comparison of the effect of loratadine on the airway and skin responses to histamine, methacholine, and allergen in subjects with asthma. J Allergy Clin Immunol. 1990;86:886–893
  17. Murdoch D, Goa KL, Keam SJ. Desloratadine. An update of its efficacy in the management of allergic disorders. Drugs. 2003;63:2051–2077
  18. Blake KV. Montelukast: data from clinical trials in the management of asthma. Ann Pharmacother. 1999;33:1299–1314
  19. Diamant Z, Grootendorst DC, Veselic-Charvat M, Timmers MC, De Smet M, Leff JA, et al. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma. Clin Exp Allergy. 1999;29:42–51
  20. Leigh R, Vethanayagam D, Yoshida M, Watson RM, Rerecich T, Inman MD, et al. Effects of montelukast and budesonide on airway responses and airway inflammation in asthma. Am J Respir Crit Care Med. 2002;166:1212–1217
  21. Palmqvist M, Bruce C, Sjostrand M, Arvidsson P, Lotvall J. Differential effects of fluticasone and montelukast on allergen-induced asthma. Allergy. 2005;60:65–70
  22. Bjorck T, Dahlen S-E. Leukotrienes and histamine mediate IgE-dependent contractions of human bronchi: pharmacological evidence obtained with tissues from asthmatic and non-asthmatic subjects. Pulm Pharmacol. 1993;6:87–96
  23. Roquet A, Dahlen B, Kumlin M, Ihre E, Anstren G, Binks S, et al. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med. 1997;155:1856–1863
  24. Ruck LM, Rizzo CA, Anthes JC, Eckel S, Egan RW, Cuss FM, et al. Synergistic antiallergic activity of combined histamine H1- and cysteinyl leukotriene1-receptor blockade in human bronchus. Life Sci. 2001;68:2825–2834
  25. Cockcroft DW, Murdock KY. Comparative effects of inhaled salbutamol, sodium cromoglycate and beclomethasone dipropionate on allergen-induced early asthmatic response, late asthmatic response and increased bronchial responsiveness to histamine. J Allergy Clin Immunol. 1987;79:734–740

 We are grateful to Merck Frosst Canada Ltd for supplying montelukast tablets and for partial funding and to Schering Canada Inc for supplying desloratadine tablets.Disclosure of potential conflict of interest: D. Cockcroft receives grants and research support from Merck Frosst Canada Inc, is on the Advisory Board for Merck Frosst Canada Inc, and receives funds from Schering Canada Inc. B. Davis and D. Todd—none disclosed.

PII: S0091-6749(05)01514-9

doi: 10.1016/j.jaci.2005.06.014

The Journal of Allergy and Clinical Immunology
Volume 116, Issue 4 , Pages 768-772 , October 2005

Article Tools

* Image Usage & Resolution